SARS-COV-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用
本发明公开了SARS‑COV‑2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用，所述的抗原多肽序列如SEQ.ID.NO.1和SEQ.ID.NO.2所示。所述的重组腺相关病毒是将将pHelper、pRep2Cap5和抗原多肽的表达载体共孵育，在转染试剂聚乙烯亚胺存在的条件下转染细胞，培育细胞后，经过裂解和纯化，得到含有重组腺相关病毒的纯化液。本发明的重组腺相关病毒在体内递送表达产生融合抗原多肽，诱导产生血清中和抗体，对SARS‑COV‑2新冠病毒具有中和效价，并持续表达，可用于对人进行针对COVID‑19新型冠状病毒肺炎的免疫接种。.
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 26. Apr. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Chinesisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-04-26, Last update posted on www.tib.eu: 2022-08-26, Last updated: 2023-02-09 |
|---|
| Patentnummer: |
CN112695057 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA011585994 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA011585994 | ||
| 003 | DE-627 | ||
| 005 | 20230504082036.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210601s2022 xx |||||o 00| ||chi c | ||
| 035 | |a (DE-627)EPA011585994 | ||
| 035 | |a (EPA)CN112695057 | ||
| 035 | |a (EPA)71908796 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 245 | 1 | 0 | |a SARS-COV-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-04-26, Last update posted on www.tib.eu: 2022-08-26, Last updated: 2023-02-09 | ||
| 520 | |a 本发明公开了SARS‑COV‑2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用，所述的抗原多肽序列如SEQ.ID.NO.1和SEQ.ID.NO.2所示。所述的重组腺相关病毒是将将pHelper、pRep2Cap5和抗原多肽的表达载体共孵育，在转染试剂聚乙烯亚胺存在的条件下转染细胞，培育细胞后，经过裂解和纯化，得到含有重组腺相关病毒的纯化液。本发明的重组腺相关病毒在体内递送表达产生融合抗原多肽，诱导产生血清中和抗体，对SARS‑COV‑2新冠病毒具有中和效价，并持续表达，可用于对人进行针对COVID‑19新型冠状病毒肺炎的免疫接种。 | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 26. Apr. |
| 773 | 1 | 8 | |g year:2022 |g day:26 |g month:04 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/71908796/publication/CN112695057A1?q=CN112695057 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | u | w | |j 2022 |b 26 |c 04 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 26 |c 04 | ||